PROCEPT BioRobotics Corporation Stock-Based Compensation
PROCEPT BioRobotics Corporation (PRCT) reported Stock-Based Compensation of $27.61 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-05
- PROCEPT BioRobotics Corporation share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $14.53M, a 19.49% increase year-over-year.
- PROCEPT BioRobotics Corporation share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $13.07M, a 29.32% increase year-over-year.
- PROCEPT BioRobotics Corporation share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $10.84M, a 19.34% increase year-over-year.
- PROCEPT BioRobotics Corporation share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $14.49M, a 70.21% increase year-over-year.
- PROCEPT BioRobotics Corporation share-based payment arrangement, noncash expense for fiscal 2025 was $47.60M, a 49.51% increase from fiscal 2024.
- PROCEPT BioRobotics Corporation share-based payment arrangement, noncash expense for fiscal 2024 was $31.84M, a 66.41% increase from fiscal 2023.
- PROCEPT BioRobotics Corporation share-based payment arrangement, noncash expense for fiscal 2023 was $19.13M, a 85.10% increase from fiscal 2022.
- PROCEPT BioRobotics Corporation share-based payment arrangement, noncash expense for fiscal 2022 was $10.34M, a 172.31% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $14.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $27.61M 10-Q · filed 2026-08-05 | $38.45M derived: sum of 3 quarters · filed 2026-08-05 | $52.94M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $13.07M 10-Q · filed 2026-04-30 | $23.91M derived: sum of 2 quarters · filed 2026-04-30 | $38.40M derived: sum of 3 quarters · filed 2026-04-30 | $50.57M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $10.84M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $25.33M derived: sum of 2 quarters · filed 2026-02-26 | $37.49M derived: sum of 3 quarters · filed 2026-08-05 | $47.60M 10-K · filed 2026-02-26 |
| 2025-09-30 | $14.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $26.65M derived: sum of 2 quarters · filed 2026-08-05 | $36.76M 10-Q · filed 2025-11-05 | $45.85M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $12.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $22.27M 10-Q · filed 2026-08-05 | $31.36M derived: sum of 3 quarters · filed 2026-08-05 | $39.87M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $10.11M 10-Q · filed 2026-04-30 | $19.19M derived: sum of 2 quarters · filed 2026-04-30 | $27.71M derived: sum of 3 quarters · filed 2026-04-30 | $35.69M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $9.09M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $17.60M derived: sum of 2 quarters · filed 2026-02-26 | $25.58M derived: sum of 3 quarters · filed 2026-02-26 | $31.84M 10-K · filed 2026-02-26 |
| 2024-09-30 | $8.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $16.50M derived: sum of 2 quarters · filed 2025-11-05 | $22.75M 10-Q · filed 2025-11-05 | $27.74M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $7.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $14.24M 10-Q · filed 2025-08-07 | $19.22M derived: sum of 3 quarters · filed 2026-02-26 | $24.55M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $6.26M 10-Q · filed 2025-05-02 | $11.24M derived: sum of 2 quarters · filed 2026-02-26 | $16.56M derived: sum of 3 quarters · filed 2026-02-26 | $21.67M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $4.98M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $10.31M derived: sum of 2 quarters · filed 2026-02-26 | $15.41M derived: sum of 3 quarters · filed 2026-02-26 | $19.13M 10-K · filed 2026-02-26 |
| 2023-09-30 | $5.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-28 | $10.43M derived: sum of 2 quarters · filed 2024-10-28 | $14.15M 10-Q · filed 2024-10-28 | $17.04M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $5.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-02 | $8.83M 10-Q · filed 2024-08-02 | $11.71M derived: sum of 3 quarters · filed 2025-02-27 | $14.94M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $3.72M 10-Q · filed 2024-05-02 | $6.61M derived: sum of 2 quarters · filed 2025-02-27 | $9.83M derived: sum of 3 quarters · filed 2025-02-27 | $12.51M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $2.88M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $6.11M derived: sum of 2 quarters · filed 2025-02-27 | $8.79M derived: sum of 3 quarters · filed 2025-02-27 | $10.34M 10-K · filed 2025-02-27 |
| 2022-09-30 | $3.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $5.90M derived: sum of 2 quarters · filed 2023-11-02 | $7.45M 10-Q · filed 2023-11-02 | $8.95M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $2.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-28 | $4.23M 10-Q · filed 2023-07-28 | $5.72M derived: sum of 3 quarters · filed 2024-02-28 | $6.65M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $1.55M 10-Q · filed 2023-05-04 | $3.05M derived: sum of 2 quarters · filed 2024-02-28 | $3.97M derived: sum of 3 quarters · filed 2024-02-28 | $4.70M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $2.42M derived: sum of 2 quarters · filed 2024-02-28 | $3.15M derived: sum of 3 quarters · filed 2024-02-28 | $3.80M 10-K · filed 2024-02-28 |
| 2021-09-30 | $925.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04 | $1.65M derived: sum of 2 quarters · filed 2022-11-04 | $2.30M 10-Q · filed 2022-11-04 | $2.90M derived: sum of 4 quarters · filed 2022-11-04 |
| 2021-06-30 | $725.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-05 | $1.38M 10-Q · filed 2022-08-05 | $1.98M derived: sum of 3 quarters · filed 2022-08-05 | |
| 2021-03-31 | $650.00K 10-Q · filed 2022-05-06 | $1.25M derived: sum of 2 quarters · filed 2022-05-06 | ||
| 2020-12-31 | $604.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-22 | $2.17M 10-K · filed 2022-03-22 | ||
| 2020-09-30 | $1.57M 10-Q · filed 2021-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Beta Bionics, Inc. (BBNX) | United States | $0.979B | -9.66 |
| TANDEM DIABETES CARE INC (TNDM) | United States | $1.059B | -16.57 |
| SpyGlass Pharma, Inc. (SGP) | United States | $0.925B | |
| IRADIMED CORP (IRMD) | United States | $1.089B | 52.92 |
| ARTIVION, INC. (AORT) | United States | $1.123B | -345.09 |
| SI-BONE, Inc. (SIBN) | United States | $0.830B | -49.82 |
| INTEGRA LIFESCIENCES HOLDINGS CORP (IART) | United States | $1.234B | -193.02 |
| MIMEDX GROUP, INC. (MDXG) | United States | $0.687B | 89.92 |
| ANGIODYNAMICS INC (ANGO) | United States | $0.632B | -13.02 |
| ORTHOPEDIATRICS CORP (KIDS) | United States | $0.592B |